Ahmet SELİM, Nilüfer KOÇAK, Hüseyin ASLANKARA, Süleyman KAYNAK

Comparative study of photodynamic therapy monotherapy versus triple management in age-related macular degeneration

To compare the effectiveness of photodynamic therapy (PDT) and PDT combined with intravitreal triamcinolone (IVTA) and vascular endothelial growth factor inhibition (anti-VEGF) in age-related macular degeneration (AMD). Materials and methods: Eighty eyes of 80 patients diagnosed with choroidal neovascularization (CNV) caused by AMD were included in the study. PDT was carried out on 40 eyes in group I, and PDT combined with 4 mg IVTA and anti-VEGF (1.25 mg bevacizumab in 20 eyes, 0.3 mg pegaptanib sodium in 20 eyes) was carried out in group II. The primary efficacy endpoint was the mean change from baseline visual acuity at month 12. Results: Mean follow-up was 14.2 ± 2.18 months in group I and 12.45 ± 2.82 months in group II. In group I there was a 2.88 logMAR line decrease and 1.95 logMAR line increase in group II in vision between pretreatment and 12th month measurements (P < 0.05). Mean PDT session was 2.00 in group I and the mean combined treatment session was 1.15 in group II in the 12th month. Conclusion: Combination of IVTA and anti-VEGF with PDT is more effective and safer than PDT monotherapy in the treatment of CNV secondary to AMD. Combination treatment decreases the frequency and number of treatment sessions for an improved visual prognosis.

Anahtar Kelimeler:

Age-related macular degeneration, bevacizumab, choroidal neovascularization, pegaptanib sodium, photodynamic therapy

Comparative study of photodynamic therapy monotherapy versus triple management in age-related macular degeneration

Keywords:

Age-related macular degeneration, bevacizumab, choroidal neovascularization, pegaptanib sodium, photodynamic therapy,

PDF

___

Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I, Zografos L, Piguet B, Donati G, Lane AM et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase I and II study. Arch Ophthalmol 1999; 117: 1177–1187.
Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Three year results from randomized clinical trials. Arch Ophthalmol 1986; 104: 694–701.
Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascula- rization. Three year results from randomized clinical trials. Five-years results from randomized clinical trials. Arch Ophthalmol 1994; 112: 500–509.
Marshall J. The ageing retina: physiology or pathology. Eye 1987; 1: 282–295.
Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000; 45: 115–134. 6. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007; 27: 133–140.
Augustin AJ, Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 141: 638–645.
D’Amico DJ, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B. VEGF inhibition study in ocular neovascularization (V.I.S.I.O.N.) clinical trial group. Pegaptanib sodium for neovascular age-related macular degeneration: two year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006; 113: 992–1001.
Rosenfeld PJ, Brown DM, Heier, JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, for the MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419–1431.
Regillo DC, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N. On behalf of the PIER Study Group. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008; 145: 239–248.
Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomize clinical trial including lesions with occult with no classic choroidal neovascularization–verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541–560.
Bressler NM. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials- TAP report 2. Arch Ophthalmol 2001; 119: 198–207.
Toklu Y, Çakmak HB, Arıkan Yorgun M, Ergun SB, Şimşek Ş. A combination therapy of half-dose verteporfin photodynamic therapy and intravitreal injection of ranibizumab for chronic central serous chorioretinopathy. Turk J Med Sci 2012; 42: 681–688.
Schmidt-Erfurth U, Niemeyer M, Geitzenauer W, Michels S. Time course and morphology of vascular effect associated with photodynamic therapy. Ophthalmology 2005; 112: 2061–2069.
Schmidt-Erfurth U, Schöltzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003; 44: 4473–4480.
Heier J, Boyer D, Ciulla T, Ferrone PJ, Jumper JM, Gentile RC, Kotlovker D, Chung CY, Kim RY; FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration. (FOCUS) Year 2 Results. Arch Ophthalmol 2006; 124: 1532– 1542.
Chan WM, Lai TYY, Wong AL, Tong JP, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularization in age related macular degeneration: a comparative study. Br J Ophthalmol 2006; 90: 337–341.
Larsen M, Schmidt-Erfurth U, Lanzetta P, Wolf S, Simader C, Tokaji E, Pilz S, Weisberger A. MONT BLANC Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology 2012; 119: 992–1000.
Kaiser PK, Boyer DS, Cruess AF, Slakter JS, Pilz S, Weisberger A. DENALI Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology 2012; 119: 1001–1010.
Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 2000; 41: 3158–3164.
Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA, Tewari A. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006; 26: 988–993.
Ahmadieh H, Taei R, Soheilian M, Riazi-Esfahani M, Karkhaneh R, Lashay A, Azarmina M, Dehghan MH, Moradian S. Single- session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmol 2007, 7: 10.
Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006; 113: 114–122.